Clinical Trial Update: A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and effectiveness of anlotinib as neoadjuvant therapy for pheochromocytoma and paraganglioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: UNKNOWN